BEXIMCO PHARMA.GDR REGS 1 Cash Flow Quality Index
BEXIMCO PHARMA.GDR REGS 1 cash flow quality index. BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Cash Flow Quality Index of 1.43x as of June 2024. Operating cash flow of €8.36 Billion exceeds net income of €5.83 Billion, indicating high earnings quality where cash backs reported profits. See R2WA free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of BEXIMCO PHARMA.GDR REGS 1 (2022–2024)
Cash flow quality index of BEXIMCO PHARMA.GDR REGS 1 from 2022 to 2024. Historical Cash Flow Quality Index for BEXIMCO PHARMA.GDR REGS 1 across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore BEXIMCO PHARMA.GDR REGS 1 (R2WA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
BEXIMCO PHARMA.GDR REGS 1 Cash Flow Quality Index by Year (2022–2024)
BEXIMCO PHARMA.GDR REGS 1 cash flow quality index by year from 2022 to 2024. Year-by-year earnings quality comparison for BEXIMCO PHARMA.GDR REGS 1. For the full cash flow conversion analysis, see R2WA cash flow metrics.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.43x | €8.36 Billion | €5.83 Billion | ▲ +8.7% |
| 2023 | 1.32x | €6.08 Billion | €4.61 Billion | ▲ +29.6% |
| 2022 | 1.02x | €5.21 Billion | €5.12 Billion | — |